Xerclear, a patented combination of 5% acyclovir and 1% hydrocortisone in Medivir’s proprietary cream formulation, is a topical product for the treatment of recurrent herpes labialis.
As per the terms of the distribution agreement, Luxembourg Pharma, a subsidiary of The Lapidot Group, an Israel-based healthcare corporation, is expected to take up the responsibility for obtaining the regulatory approvals, and for marketing, sales and distribution of Medivir’s cold sore product in the territory.
In consideration of the rights granted to Luxembourg Pharma, Medivir is expected to receive revenues from Xerclear sales.
Medivir CEO Ron Long said that they were pleased to announce a distribution partner for Xerclear.
Luxembourg Pharma president and CEO Ilan Lapidot said that they were pleased to be working with Medivir to distribute the product in their local market.